Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Fish

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|July 5, 2024
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2021
1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK propertiesChristian Nilewski, Theodore D Michels, Garrick K Packard, et al.
Molecular Cancer Therapeutics|June 22, 2024
Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery and Structural Optimization of BRD4-Selective Monovalent Direct DegradersGeoffray Leriche, Farhana Barmare, Julia I Toth, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 15, 2026
Heterogenous Neuropathology in a Pedigree with RAB39B-Related Parkinson's DiseaseCaitlin Latimer, Oswaldo Lorenzo-Betancor, Dong-Hui Chen, et al.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|July 5, 2024
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2021
1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK propertiesChristian Nilewski, Theodore D Michels, Garrick K Packard, et al.
Molecular Cancer Therapeutics|June 22, 2024
Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery and Structural Optimization of BRD4-Selective Monovalent Direct DegradersGeoffray Leriche, Farhana Barmare, Julia I Toth, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 15, 2026
Heterogenous Neuropathology in a Pedigree with RAB39B-Related Parkinson's DiseaseCaitlin Latimer, Oswaldo Lorenzo-Betancor, Dong-Hui Chen, et al.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Pageof 2